enVVeno Medical Corporation

Stage 4 · Declining · week 5

As of Oct 22, 2026, enVVeno Medical is in Stage 4, the downtrend phase, now in week 5 (since Sep 21, 2026). It closed at $6.91, 72.6% below its 52-week high and below its 200-day average, which is falling.

$6.91

-5.73% today

$4.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NVNO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 20w

S4 31w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 4w → S2 9w → S3 5w → S4 7w → S1 1w → S2 12w → S3 9w → S2 11w → S3 1w → S4 20w → S1 4w → S4 8w → S1 4w → S2 10w → S3 3w → S4 31w → S1 4w → S4 11w → S1 7w → S4 5w current

Total tracked: 166 weeks across 20 stage runs.

NVNO among Medical Devices103rd of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…103	NVNOenVVeno Medical Corporation	Stage 4 · wk 5	14	−22.9%

vs 52W High

-72.6%

$6.91 lo$25.24 hi

72.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 5

1w13w26w

Week 5, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-33.9%

200 DMA: $10.46 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.05x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-22.9%

-33.5%

-46.6%

YTD

-43.6%

-72.9%

Scan Membership

Breakout Watch

Latest: 2025-06-20

7 appearances in last 60 days. First seen: 2019-05-14.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 5 · Vol 1.05x

2026-10-21S4

Wk 5 · Vol 1.60x

2026-10-20S4

Wk 5 · Vol 3.94x

2026-10-19S4

Wk 5 · Vol 1.29x

2026-10-16S4

Wk 4 · Vol 2.49x

2026-10-15S4

Wk 4 · Vol 1.59x

2026-10-14S4

Wk 4 · Vol 0.72x

2026-10-13S4

Wk 4 · Vol 1.92x

2026-10-12S4

Wk 4 · Vol 5.36x

2026-10-09S4

Wk 3 · Vol 1.64x

2026-10-08S4

Wk 3 · Vol 0.30x

2026-10-07S4

Wk 3 · Vol 0.69x

Moving averages & range

50 DMA

$9.46

200 DMA

$10.46

52W High

$25.24

52W Low

$6.91

5D Low

$6.91

Resistance levels (recent highs)

20d High

$8.81

60d High

$11.80

120d High

$11.80

250d High

$25.20

Next resistance

+27.5%

to 20d High

ROE

-58.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.2

enVVeno Medical: quick answers

What stage is enVVeno Medical in?

As of Oct 22, 2026, enVVeno Medical (NVNO) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 21, 2026 and is in week 5. What the four stages mean

Is enVVeno Medical in an uptrend?

No. enVVeno Medical is in a Stage 4 downtrend. It trades 33.9% below its 200-day average, which is falling.

How far is enVVeno Medical from its 52-week high?

enVVeno Medical closed at $6.91 on Oct 22, 2026, 72.6% below its 52-week high of $25.24. Its 52-week low is $6.91.

How has enVVeno Medical performed over the past year?

As of Oct 22, 2026, enVVeno Medical is down 72.9% over the past year and down 43.6% so far in 2026.

Which sector and industry is enVVeno Medical in?

enVVeno Medical is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.